VivoSeq
Cardiovascular

Atrial Fibrillation

294

Pipeline Programs↗

139

Active Trials↗

74

Companies Involved↗

Atrial Fibrillation is a highly competitive landscape with 294 programs across 74 companies. The most active players are Beijing Suncadia Pharmaceuticals Co., Ltd, GSK, ARYx Therapeutics. 105 therapies are approved with 57 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

88/100

Pipeline Velocity

66/100

Mech. Concentration

7/100

Completion Rate

82/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Beijing Suncadia Pharmaceuticals Co., Ltd

1 program

Phase 1GSK logo

GSK

2 programs

Phase 2A

ARYx Therapeutics

2 programs

Phase 2A

Anthos Therapeutics, Inc.

2 programs

Phase 2A

Acesion Pharma

2 programs

Phase 2Regeneron logo

Regeneron

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical71

Zanubrutinib

BeOne Medicines

Atenolol

Twinpig Biolab, Inc.

Calcium

Eli Lilly

Rituximab

Roche

Ibrutinib

Pharmacyclics LLC.

Phase 111

Triiodothyronine

Hadassah Medical Organization

Human Amniotic Membrane

University of Utah

OPC-108459

Otsuka

Eplereone

Assiut University

Injection of BEP 800

Institut National de la Santé Et de la Recherche Médicale, France

Phase 250

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Canakinumab

Novartis

Tirzepatide

Eli Lilly

Melatonin

Neurim Pharmaceuticals Ltd.

Esmolol

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 357

Dabigatran

Boehringer Ingelheim

Candesartan

AstraZeneca

Semaglutide

Novo Nordisk

Ramipril

Viking Therapeutics, Inc.

Alcohol

Astellas

Approved105

Fondaparinux

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Dexamethasone

Aspen Global Incorporated

Flecainide

Alvogen Korea

Pantoprazole

Wyeth-Lederle Vaccines

Eplerenone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Analysis

Modality Breakdown

98%

Small molecule

358 of 364 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody3<1%Peptide3<1%

Small molecule leads; the ring shows all 364 classified programs, each share of the total. Modality classified for 99% of 377 pipeline programs.

Analysis

Trial Status

622

clinical trials

Completed318 · 51%
Unknown status97 · 16%
Recruiting79 · 13%
Terminated55 · 9%
Not yet recruiting37 · 6%
Active, not recruiting20 · 3%
Other16 · 3%

Clinical Trials

Trial Activity

622 trials

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Recruiting·JJohns Hopkins University·Phase 3·NCT05836987·5,350 enrolled
AV Junction Ablation or Optimal Medical Treatment in PatiEnts With Cardiac Resynchronization Therapy and Permanent Atrial Fibrillation
Recruiting·UUniversity Hospital Ostrava·N/A·NCT05776797·480 enrolled
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Recruiting·UUniversity of Chicago·Phase 3·NCT06499857·200 enrolled
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
Recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT06067438·90 enrolled
Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
Recruiting·KKorea University Anam Hospital·Phase 4·NCT06187311·940 enrolled
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation
Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT05955365·3,010 enrolled
Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT06125925·436 enrolled
The Effect of Beta-blocker on Chronotropic Response and Cardiorespiratory Fitness in Patients With Atrial Fibrillation
Recruiting·NNational Taiwan University Hospital·N/A·NCT05332457·40 enrolled
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
Recruiting·NNova Scotia Health Authority·N/A·NCT07272902·84 enrolled
The Effect of Colchicine on the Occurrence of Atrial Fibrillation After Cardiac Surgery
Recruiting·—·Phase 4·NCT06798714·140 enrolled
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation
Recruiting·UUniversity of Birmingham·Phase 4·NCT04700826·3,000 enrolled
Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
Recruiting·SScarborough General Hospital·Phase 4·NCT07173855·3,253 enrolled
Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy After Left Atrial Appendage Closure With the LAmbre Device in Patients With Nonvalvular Atrial Fibrillation: A Multinational Real-world Registry
Recruiting·FFundación EPIC·N/A·NCT06620757·234 enrolled
RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
Recruiting·—·Phase 3·NCT07187570·1,600 enrolled
Remimazolam for Postoperative Atrial Fibrillation
Recruiting·YYangzhou University·N/A·NCT05891145·50 enrolled
Page 1 of 42

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)